Intriguingly, 2 patients with CML receiving gliptins for concomitant diabetes mellitus had a decrease of BCR/ABL1 transcript levels during treatment. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.